80573-04-2
80573-04-2
Chemical Structure
Balsalazide
- CAS. Nr.: 80573-04-2
- Formula:C17H15N3O6
- Molecular Weight:357.32
IUPAC Name: (E)-5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid
InChIKey: IPOKCKJONYRRHP-FMQUCBEESA-N
SMILES: O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O
Biological Activity: Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Balsalazide | 98.65% | Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Balsalazide-d4 | 99.9% | Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Balsalazide-d3 | Balsalazide-d3 is the deuterium labeled Balsalazide (HY-B0667). Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. [Content Brief]
- [2]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. [Content Brief]
- [3]. Seema A Patil, et al. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr;2(2):177-84. [Content Brief]
